UY25421A1 - VITRONECTIN RECEPTOR ANTAGONISTS - Google Patents

VITRONECTIN RECEPTOR ANTAGONISTS

Info

Publication number
UY25421A1
UY25421A1 UY25421A UY25421A UY25421A1 UY 25421 A1 UY25421 A1 UY 25421A1 UY 25421 A UY25421 A UY 25421A UY 25421 A UY25421 A UY 25421A UY 25421 A1 UY25421 A1 UY 25421A1
Authority
UY
Uruguay
Prior art keywords
vitronectin receptor
receptor antagonists
stenosis
osteoporosis
atherosclerosis
Prior art date
Application number
UY25421A
Other languages
Spanish (es)
Inventor
W Miller J Gleason D Uzinskas
Peter J Manley
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Priority to UY25519A priority Critical patent/UY25519A1/en
Publication of UY25421A1 publication Critical patent/UY25421A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Esta invención se refiere a compuestos farmacéuticamente activos que inhiben el receptor de vitronectina y son útiles para el tratamiento de inflamación, cáncer y trastornos cardiovasculares, tales como aterosclerosis y estenosis, y enfermedades en las que la resorción ósea es un factor, tal como la osteoporosis.This invention relates to pharmaceutically active compounds that inhibit the vitronectin receptor and are useful for the treatment of inflammation, cancer, and cardiovascular disorders, such as atherosclerosis and stenosis, and diseases in which bone resorption is a factor, such as osteoporosis. .

UY25421A 1998-03-10 1999-03-10 VITRONECTIN RECEPTOR ANTAGONISTS UY25421A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UY25519A UY25519A1 (en) 1998-03-10 1999-05-19 PROCEDURE FOR PREPARING VITRONECTIN RECEPTOR ANTAGONIST

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7761098P 1998-03-10 1998-03-10
US9606398P 1998-08-11 1998-08-11

Publications (1)

Publication Number Publication Date
UY25421A1 true UY25421A1 (en) 2001-07-31

Family

ID=26759473

Family Applications (2)

Application Number Title Priority Date Filing Date
UY25421A UY25421A1 (en) 1998-03-10 1999-03-10 VITRONECTIN RECEPTOR ANTAGONISTS
UY25519A UY25519A1 (en) 1998-03-10 1999-05-19 PROCEDURE FOR PREPARING VITRONECTIN RECEPTOR ANTAGONIST

Family Applications After (1)

Application Number Title Priority Date Filing Date
UY25519A UY25519A1 (en) 1998-03-10 1999-05-19 PROCEDURE FOR PREPARING VITRONECTIN RECEPTOR ANTAGONIST

Country Status (24)

Country Link
EP (1) EP1061921A4 (en)
JP (1) JP2002506033A (en)
KR (1) KR20010041812A (en)
CN (1) CN1299282A (en)
AP (1) AP2000001898A0 (en)
AR (1) AR015241A1 (en)
AU (1) AU758498B2 (en)
BG (1) BG104824A (en)
BR (1) BR9908636A (en)
CA (1) CA2323208A1 (en)
CO (1) CO5080762A1 (en)
DZ (1) DZ2741A1 (en)
EA (1) EA200000921A1 (en)
HU (1) HUP0101143A3 (en)
ID (1) ID26223A (en)
IL (1) IL138245A0 (en)
NO (1) NO20004503L (en)
OA (1) OA12189A (en)
PE (1) PE20000323A1 (en)
PL (1) PL342881A1 (en)
SK (1) SK13292000A3 (en)
TR (1) TR200002625T2 (en)
UY (2) UY25421A1 (en)
WO (1) WO1999045927A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19939981A1 (en) * 1999-08-24 2001-03-01 Merck Patent Gmbh New inhibitors of the integrin alphavß3
DE19939980A1 (en) 1999-08-24 2001-03-01 Merck Patent Gmbh Inhibitors of the integrin alphavbeta¶3¶
US6881736B1 (en) 1999-09-07 2005-04-19 Smithkline Beecham Corporation Vitronectin receptor antagonists
EG24179A (en) * 1999-09-07 2008-09-28 Smithkline Beecham Corp Vitronectin receptor antagonists
GB9930570D0 (en) * 1999-12-23 2000-02-16 Pfizer Ltd Therapy
US6448278B2 (en) 1999-12-23 2002-09-10 Pfizer Inc. Procollagen C-proteinase inhibitors
FR2808798A1 (en) * 2000-05-09 2001-11-16 Hoechst Marion Roussel Inc New N-heterocyclyl-aminoacid derivatives and analogs, are vitronectin analogs useful e.g. for treating osteoporosis, tumor growth or metastasis, inflammation or cardiovascular disease
AU2001269821A1 (en) 2000-06-15 2001-12-24 Barbara Chen Cycloalkyl alkanoic acids as integrin receptor antagonists
US6531494B1 (en) 2001-08-29 2003-03-11 Pharmacia Corporation Gem-substituted αvβ3 antagonists
US6645993B2 (en) 2001-03-30 2003-11-11 Warner-Lambert Company 3-heterocyclylpropanohydroxamic acid PCP inhibitors
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
WO2005049589A2 (en) * 2003-10-14 2005-06-02 Cadila Healthcare Limited Heterocyclic compounds for the treatment of hyperlipidemia, diabetes, obesity and similar diseases
MY146532A (en) * 2004-03-05 2012-08-15 Taisho Pharmaceutical Co Ltd Thiazole derivative
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
EP1879864A1 (en) 2005-04-20 2008-01-23 Janssen Pharmaceutica N.V. Fluorinated pyridine n-oxide thrombin modulators and process for n-oxidation of nitrogen containing heteroaryls
US10059663B2 (en) 2013-08-29 2018-08-28 Kyoto Pharmaceutical Industries, Ltd. Aromatic compound and use thereof
EP4249471A3 (en) 2013-09-24 2023-10-18 FUJIFILM Corporation Pharmaceutical composition of a nitrogen-containing compound or salt thereof, or metal complex thereof
WO2015181676A1 (en) 2014-05-30 2015-12-03 Pfizer Inc. Carbonitrile derivatives as selective androgen receptor modulators
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2241724A1 (en) * 1995-12-29 1997-07-10 Smithkline Beecham Corporation Vitronectin receptor antagonists
TR199801254T2 (en) * 1995-12-29 1998-10-21 Smithkline Beecham Corporation Vitronectin receptor antagonists.

Also Published As

Publication number Publication date
CA2323208A1 (en) 1999-09-16
AR015241A1 (en) 2001-04-18
EA200000921A1 (en) 2001-04-23
SK13292000A3 (en) 2001-06-11
AP2000001898A0 (en) 2000-09-30
CO5080762A1 (en) 2001-09-25
NO20004503D0 (en) 2000-09-08
EP1061921A1 (en) 2000-12-27
HUP0101143A3 (en) 2002-12-28
NO20004503L (en) 2000-10-10
AU758498B2 (en) 2003-03-20
WO1999045927A1 (en) 1999-09-16
AU2903399A (en) 1999-09-27
KR20010041812A (en) 2001-05-25
BG104824A (en) 2001-05-31
PL342881A1 (en) 2001-07-16
TR200002625T2 (en) 2000-12-21
HUP0101143A2 (en) 2001-08-28
UY25519A1 (en) 1999-12-13
ID26223A (en) 2000-12-07
IL138245A0 (en) 2001-10-31
BR9908636A (en) 2002-01-08
EP1061921A4 (en) 2005-03-30
PE20000323A1 (en) 2000-05-24
CN1299282A (en) 2001-06-13
OA12189A (en) 2006-05-09
DZ2741A1 (en) 2003-09-08
JP2002506033A (en) 2002-02-26

Similar Documents

Publication Publication Date Title
UY25421A1 (en) VITRONECTIN RECEPTOR ANTAGONISTS
AR010873A1 (en) VITRONECTIN RECEPTOR ANTAGONIST COMPOUNDS, INTERMEDIARIES, METHODS OF THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS, USE OF SUCH COMPOUNDS FOR THE MANUFACTURE OF MEDICINES.
AR005987A1 (en) COMBINED THERAPY FOR OSTEOPOROSIS
ES2134859T3 (en) DERIVATIVES OF 4-CARBOXOAMIDO-PIPERIDINE, INTERMEDIATE PRODUCTS AND USE AS NEUROKININE ANTAGONISTS.
GT199900070A (en) DERIVATIVES OF ISOTIAZOLE, USEFUL AS ANTI-CANCER AGENTS.
ES2194223T3 (en) INTEGRINE ANTAGONISTS.
ES2074736T3 (en) PROCEDURE FOR THE PRODUCTION OF POLYFLUOROOLEFINS.
ATE294163T1 (en) INTEGRIN RECEPTOR ANTAGONISTS
PA8452701A1 (en) PROSTAGLANDIN AGONISTS
IS5513A (en) Intergrin receptor antagonists
ATE299023T1 (en) INTEGRIN RECEPTOR ANTAGONISTS
EA200500250A1 (en) TIOMOLIBDATA ANALOGUES AND THEIR APPLICATION
BR0310087A (en) Hyaluronic acid injectable solid carriers for application of osteogenic proteins
BR0105457A (en) Therapeutic combinations to stimulate bone growth
CO5611124A2 (en) BENZOFURAN DERIVATIVES SUBSTITUTED USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS
DE60015508D1 (en) C-16 UNSATURATED FP-SELECTIVE PROSTAGLANDIN ANALOG
UY25824A1 (en) VITRONECTIN RECEPTOR ANTAGONIST
DK1756046T3 (en) Arylalkylsulfonamides as therapeutic agents for the treatment of bone disorders
AR025589A1 (en) ANTIGONISTS OF VITRONECTINE RECEPTORS.
UY26473A1 (en) ACTIVE COMPOUNDS IN THE GLUCOCORTICOID RECEPTOR
ECSP003747A (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF PULMONARY DISEASES
GT199900083A (en) THERAPEUTIC COMBINATIONS FOR MUSCULOSKELETAL FRAGILITY.
AR042065A1 (en) A METHOD FOR PREPARING INDANO-1,3-DICARBOXYL ACID
BR9811819A (en) 2-acylaminopropanamines as tachykinin receptor antagonists
UY26651A1 (en) COMBINED THERAPY FOR OSTEOPOROSIS

Legal Events

Date Code Title Description
ABAN Application deemed to be withdrawn (no publication fee paid)

Effective date: 20090715